2025-09-15 15:14 |
Detailed record - Similar records
|
2025-09-15 15:12 |
Detailed record - Similar records
|
2025-09-15 15:10 |
Detailed record - Similar records
|
2025-09-15 15:07 |
Detailed record - Similar records
|
2025-09-15 15:03 |
Detailed record - Similar records
|
2025-09-15 14:57 |
[DKFZ-2025-01909]
Journal Article
Funk, M. A. ; Theurich, S.
Targeting BCMA in CIDP: Valuable insights gained through multi-omics immune monitoring.
Dong et al. present two patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP), who received treatment with B-cell-maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cells.1 Extensive concomitant immune monitoring provides insights into the pathogenesis and mechanisms of relapse in CIDP that may help to determine the role of BCMA-targeted CAR-T cell therapy for this disease in the future..
Detailed record - Similar records
|
2025-09-15 14:56 |
Detailed record - Similar records
|
2025-09-15 14:55 |
[DKFZ-2025-01907]
Journal Article
Wansch, K. ; Pelzer, U. ; Schneider, F. ; et al
Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids.
Patient-Derived Organoids (PDOs) represent a promising technology for therapy prediction in pancreatic cancer, with the potential of enhancing treatment outcomes and allowing more effective, personalized treatment choices. However, classification approaches into sensitive and resistant models remain very variable and are based on single-agent testing only, neglecting interactive effects of multi-drug combinations. [...]
Detailed record - Similar records
|
2025-09-15 14:53 |
Detailed record - Similar records
|
2025-09-15 14:51 |
Detailed record - Similar records
|
|
|